- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00815880
C-Pulse IDE Feasibility Study- A Heart Assist System
C-Pulse Implantable Counterpulsation Pump (ICP) Feasibility Study - A Heart Assist System
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Sunshine Heart Inc. is sponsoring a prospective, multi-center trial to assess the safety and provide indications for performance of the Sunshine Heart C-PulseTM System ("C-Pulse™").
The current need is for a counterpulsation device or method that is effective enough to make its application appealing as a long-term implant to a large number of patients and physicians. It must be simple and safe, with a straight-forward implant procedure, and with long-term measurable patient benefits. Further, it would be advantageous for the counterpulsation device to be smaller, easier to insert, ambulatory, disconnectable, and not in the bloodstream. Such a device may be more readily adopted by a wider group of cardiologists and surgeons, and be suitable for a wider group of people in NYHA Class III or IV heart failure. It is important to point out that a counterpulsation device is aimed to augment native heart function and is fundamentally different from total artificial hearts, left ventricular assist devices and heart transplants which are meant to be a total replacement or an alternative to the native heart. Thus, the counterpulsation device is considered non-obligatory and not life-supporting.
Sunshine Heart, Inc has proposed C-Pulse™, a novel ambulatory, non-obligatory, non-blood contacting extra-ascending aortic counterpulsation system. The C-Pulse™ System is designed to be implanted without the need for cardiopulmonary bypass or extensive dissection, to be able to be activated immediately, to augment heart function in a safe manner and to provide sustained relief from heart failure symptoms. It can be turned off safely, and similarly, in failure modes, is considered to have an associated low risk of death or disability, other than the recurrence of heart failure symptoms. C-Pulse™ is not an alternative to the heart, it is an augmentation device, and it does not preclude the use of therapies that provide full circulatory support such as heart transplantation or LVADs.
The C-Pulse™ System consists of a counterpulsation Cuff secured around the outside of the ascending aorta, the main blood vessel out of the heart. The Cuff and a heart signal sensing wire are attached to an external driver. The external Driver inflates and deflates the Cuff in sequence with the ECG signal to assist heart function and improve the pumping capacity of the heart. The Cuff deflects the aorta in a "thumb-printing" manner which has been optimized to minimize aortic wall strain and maximize blood volume displacement per beat. The C-Pulse™ System is non-blood contacting, simple to insert, and can be turned on and off as required; all natural blood pathways are maintained - there is no exposure of foreign material to the bloodstream.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35294
- University of Alabama at Birmingham
-
-
Kentucky
-
Louisville, Kentucky, United States, 40202
- University of Louisville
-
-
Minnesota
-
Saint Paul, Minnesota, United States, 55102
- St. Paul Heart Clinic
-
-
Missouri
-
Kansas City, Missouri, United States, 64111
- Mid America Heart Institute-Saint Luke's Hospital
-
-
Ohio
-
Columbus, Ohio, United States, 43210
- Ohio State University
-
-
Pennsylvania
-
Hershey, Pennsylvania, United States, 17033
- Penn State Milton S. Hershey Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patient has ACC/AHA Stage C heart failure and remains in NYHA Class III - ambulatory Class IV despite optimal medical therapy.
- ACE inhibitor or ARB (Angiotensin Receptor Blocks) at least 30 days preceding implant or nitrate/hydralazine at the investigators discretion
- Beta-blocker for at least 90 days and stable for 30 days preceding implant
- Patient has left ventricular ejection fraction (LVEF) ≤ 35%
- Patient has had Cardiac Resynchronization Therapy (CRT) for at least 90 days prior to enrollment or is not indicated for a CRT device
- Patient has had an implanted cardio-defibrillator (ICD) at least 30 days prior to enrollment or is not indicated for ICD implantation.
- Patient is at least 18 years of age and not older than 75 years
- Patient six minute hall walk assessment between 100-350 meters
- Patient understands the nature of the procedure, is willing to comply with associated follow-up evaluations, and provide written informed consent prior to the procedure
Exclusion Criteria:
Patient has any evidence of:
- Ascending aortic calcification on posterior-anterior or lateral chest x-ray at initial screening OR
- Atherosclerotic ascending aortic disease, specifically intimal thickening greater than 3mm or mobile atheroma (moderate) or mural calcification (severe) as detected by CT scan or echocardiography (Echo)
- Patient has ascending aorto-coronary artery bypass grafts, history of aortic dissection, Marfans disease or other connective tissue disorder or has had an aortic root replacement
- Patient aorta not conforming to specified dimensional constraints defined by CT scan, most specifically mid ascending aortic outside diameter less than 29mm or greater than 40mm
- Patient has severe mitral valve incompetence, grade 4+
- Patient has moderate to severe aortic valve incompetence, grade 2-4+
- Patient has systolic blood pressure less than 90 or greater than 140 mmHg
- Patient has a Serum Sodium less than 130 mEq/L
- Patient has a Estimated Glomerular Filtration Rate (GFR) less than 40 ml/min/1.73m2
- Patient has any two of three of Bilirubin, Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT) greater than three times upper limit of normal
- Patient has a serum Albumin less than 3.0 g/dL
- Patient has Body Mass Index (BMI) less than 18 or greater than 40 kg/m2
- Men with Peak Oxygen Uptake (VO2) of greater than 18 ml/kg/min or less than 10 ml/kg/min OR -Women with Peak VO2 of greater than 16 ml/kg/min or less than 9 ml/kg/min
- Patient has any active infection
- Patient has had a myocardial infarction (MI), stroke, transient ischemic attack (TIA), cardiac or other major surgery, in the 90 days prior to enrollment
- Patient has severe Chronic Obstructive Pulmonary Disease (COPD) as evidenced by Forces Expiratory Volume (FEV1) less than or equal to 0.9 L/min
- Patient requires a concomitant surgical procedure [i.e. coronary artery bypass graft (CABG), Valve repair]
- Patient is supported with a left ventricular assist device or IABP
- Severe Right Heart Dysfunction with systemic venous congestion evidenced by clinical signs/symptoms such as Central Venous Pressure (CVP) ≥ 20 mmHg, Cardiac Index (CI) < 2.0 l/min./m2, elevated liver function tests beyond three time the upper limit of normal and presence of ascites
- Patient has reversible causes of heart failure that may be remedied by conventional surgery or other intervention
- Patient is pregnant; Note: Negative pregnancy test required in all women of child bearing potential
- Patient has any other condition that, in the opinion of the investigators, would disqualify the patient for inclusion in the study, limits survival to less than one year, or not permit valid consideration
- Patient is currently enrolled or has participated in the last 30 days in another therapeutic or interventional clinical study that is likely to confound study results
- Patient has symptomatic Carotid artery disease or asymptomatic disease with a stenosis greater than 70%.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Implantable Counterpulsation Therapy
The primary study population will include 20 patients enrolled and implanted with C-Pulse.
This expansion protocol will allow up to 40 patients to be enrolled and implanted.
Patients that meet eligibility will be enrolled and implanted into the treatment arm of the study.
These patients will receive the C-Pulse System Implant as intervention therapy.
There is not a control arm in this feasibility study.
|
Implantation and activation of counterpulsation therapy for the full duration of the study period.
The device may be turned off briefly for personal hygiene, etc.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Surviving Participants That Completed the Study
Time Frame: 5 Years
|
Amount of participants that did not exit study for reasons including worsening heart failure resulting in hospitalization, LVAD implantation, study withdrawal or death.
|
5 Years
|
Six Minute Walk Test
Time Frame: 6 Months
|
6MWT in distance (meters).
|
6 Months
|
Cardiopulmonary Exercise Testing
Time Frame: 6 Months
|
CPX is performed on a treadmill and carried out to a symptomatic maximum.
Minute oxygen consumption (VO2; ml/min) and minute carbon dioxide production (VCO2; ml/min) are measured using a breath-by-breath respiratory gas analyzer.
The Respiratory Exchange Ratio (RER) is calculated as VCO2/VO2.
A peak RER of ≥1.10 is generally considered an indication of excellent subject effort during CPX.
Achievement of a peak RER <1.00 in a CPX that is terminated by subject request, absent any electrocardiographic or hemodynamic abnormalities, generally reflects submaximal cardiovascular effort.
|
6 Months
|
Kansas City Cardiomyopathy Questionnaire (KCCQ)
Time Frame: 6 Months
|
Overall KCCQ score, a 23-item self-administered questionnaire developed to independently measure the patient's perception of their health status, which includes heart failure symptoms, impact on physical and social function, and how their heart failure impacts their quality of life (QOL) within a 2-week recall period.
Scores range from 0-100, in which higher scores reflect better health status.The KCCQ instrument may be used by medical device companies and sponsor-investigators for evaluation of safety and effectiveness for heart failure medical devices to support regulatory submissions.
The KCCQ instrument, specifically the Symptom Domain Score, Physical Limitation Domain Score, Social Limitation Domain Score, Quality of Life Domain Score and Overall Summary Score, can be used as a component of a composite primary endpoint or secondary endpoint in a feasibility or pivotal clinical trial evaluating heart failure medical devices.
|
6 Months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
New York Heart Association (NYHA) Classification
Time Frame: 6 Months
|
The most commonly used heart failure classification system, the NYHA Functional Classification, classifies patients' heart failure according to the severity of their symptoms.
It places patients in one of four categories based on how much they are limited during physical activity (I: No limitation of physical activity, II: Slight limitation of physical activity and comfortable at rest, III: Marked limitation of physical activity and comfortable at rest, IV: Unable to carry on any physical activity without discomfort, and symptoms of heart failure at rest).
|
6 Months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Pat McCarthy, MD, Northwestern University
- Principal Investigator: William T Abraham, MD, Ohio State University
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PRO02291
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Heart Failure
-
Tufts Medical CenterMetro West Medical CenterCompletedCongestive Heart Failure | Diastolic Heart Failure | Systolic Heart FailureUnited States
-
Abbott Medical DevicesCompletedHeart Failure | Heart Failure, Diastolic | Heart Failure, Systolic | Heart Failure NYHA Class II | Heart Failure NYHA Class III | Heart Failure With Reduced Ejection Fraction | Heart Failure NYHA Class IV | Heart Failure With Normal Ejection Fraction | Heart Failure; With Decompensation | Heart Failure...United States, Canada
-
Manipal UniversityUnknownHeart Failure | Decompensated Heart Failure | Acute Heart Failure | Diastolic Heart Failure | Systolic Heart FailureIndia
-
University Hospital, MontpellierCompletedHeart Failure | Diastolic Heart Failure | Systolic Heart Failure Stage CFrance
-
VA Eastern Colorado Health Care SystemNational Institute on Aging (NIA)CompletedHeart Failure | Heart Failure, Diastolic | Heart Failure, Systolic | Heart Failure With Reduced Ejection Fraction | Heart Failure With Preserved Ejection Fraction | Heart Failure; With Decompensation | Heart Failure,Congestive | Heart Failure AcuteUnited States
-
Wake Forest UniversityCompletedHeart Failure, Congestive | Heart Failure With Preserved Ejection Fraction
-
Lancaster General HospitalLouise von Hess Medical Research InstituteEnrolling by invitationDiastolic Heart FailureUnited States
-
Giresun UniversityIstanbul University - Cerrahpasa (IUC)RecruitingHeart Failure | Diastolic Heart Failure | Systolic Heart FailureTurkey
-
Wake Forest UniversityNational Institute on Aging (NIA)CompletedHeart Failure, Congestive | Diastolic Heart FailureUnited States
-
US Department of Veterans AffairsCompleted
Clinical Trials on C-Pulse™ (Implantable Counterpulsation Therapy)
-
Nuwellis, Inc.Terminated
-
Nuwellis, Inc.Terminated
-
Abbott Medical DevicesWithdrawn
-
Nora VanegasRecruitingParkinson DiseaseUnited States
-
Nora VanegasEnrolling by invitation
-
Medtronic Cardiac Rhythm and Heart FailureCompletedMagnetic Resonance Imaging | Cardiac Pacemaker, ArtificialNetherlands, Switzerland, Israel, Germany, Canada, United States, United Kingdom, Australia, Hungary, Italy, Austria, Belgium, France
-
Vanderbilt University Medical CenterAbbott Medical DevicesActive, not recruitingBilateral Vocal Fold Paralysis (BVFP)
-
Roswell Park Cancer InstituteCompletedStage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Recurrent Non-Small Cell Lung Carcinoma | Stage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung CarcinomaUnited States
-
GenmabAbbVieRecruitingFollicular Lymphoma | Diffuse Large B-Cell LymphomaUnited States, France, Italy, Spain, United Kingdom, Belgium, Denmark, Netherlands, Finland, Czechia, Sweden, Australia, Norway